SCHEMBL656591

SCHEMBL656591

CCOC(=O)CN(C(=O)Cc1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.52
CNR1 P21554 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 1/20 0.48
GAA P10253 1/20 0.47
HDAC1 Q13547 4/20 0.45
HDAC6 Q9UBN7 4/20 0.45
PRSS12 P56730 1/20 0.44
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
KLK7 P49862 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9484542 0.95 CNR2 (0.52) CNR2CNR1SMN1; SMN2MAPTGAA
SCHEMBL9366543 0.90 SMN1; SMN2 (0.56) CNR2SMN1; SMN2GAAHDAC1HDAC6
SCHEMBL657395 0.87 SMN1; SMN2 (0.61) CNR2CNR1SMN1; SMN2MAPTHDAC1
SCHEMBL9483910 0.87 TDP1 (0.53) CNR2SMN1; SMN2MAPTGAAHDAC1
SCHEMBL9483919 0.86 SMN1; SMN2 (0.44) CNR2SMN1; SMN2MAPTGAATSHR
SCHEMBL9366335 0.86 SMN1; SMN2 (0.49) CNR2SMN1; SMN2MAPTGAAHDAC1
SCHEMBL656829 0.83 CNR2 (0.52) CNR2CNR1SMN1; SMN2MAPTHDAC1
SCHEMBL9369800 0.82 GAA (0.48) CNR2SMN1; SMN2GAANPSR1KDM4E
SCHEMBL9483914 0.82 TDP1 (0.56) CNR2SMN1; SMN2MAPTGAATSHR
SCHEMBL9484509 0.81 CNR2 (0.44) CNR2SMN1; SMN2MAPTGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2349999-B1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIV SAARLAND (DE) 2016-01-27 EP disclosed
US-8912186-B2 Allosteric protein kinase modulators UNIVERSITAET DES SAARLANDES (DE) 2014-12-16 US disclosed
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2012-02-23 US disclosed
EP-2349999-A1 ALLOSTERIC PROTEIN KINASE MODULATORS Universität des Saarlandes (DE) 2011-08-03 EP disclosed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 WO disclosed
EP-2177510-A1 Allosteric protein kinase modulators Universität des Saarlandes (DE) 2010-04-21 EP disclosed
EP-0409163-B1 Novel cyclic vinylogous N-hydroxy-N-methylureas useful as 5-lipoxygenase inhibitors MERRELL DOW PHARMA (US) 1994-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS AURKC, AURKA, AURKB CNR2 4264/4885CNR1 4048/4885SMN1; SMN2 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.